# SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Source: https://onco.cc/trials/nct04079166/  
OnCo record `nct04079166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SCIB1 or iSCIB1+ DNA vaccine in melanoma, run by Scancell Ltd, active and no longer recruiting.

## Summary

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) is a phase 2 interventional study registered as NCT04079166 by Scancell Ltd, with 173 participants enrolled, started 2019-08-19 and due to reach its primary completion in 2027-01-31. Interventions recorded: SCIB1 or iSCIB1+ DNA vaccine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04079166
- Phase: 2
- Setting: A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
- Sponsor: Scancell Ltd
- Enrolled: 173

## Sources

- ClinicalTrials.gov NCT04079166: https://clinicaltrials.gov/study/NCT04079166

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Scancell](https://onco.cc/companies/scancell/)

---
JSON: https://onco.cc/api/v1/entities/nct04079166.json